Relmapirazin

The prevalence of hyperuricemia and gout continues to rise globally, and there is an urgent clinical demand for therapeutic drugs with both uric acid-lowering efficacy and good tolerance. Remepiazine belongs to a new class of selective uric acid reabsorption inhibitors (SUR1 inhibitors). It specifically inhibits the activity of uric acid transporters URAT1 and GLUT9 in renal tubules, reduces uric acid reabsorption and increases uric acid excretion, thereby lowering serum uric acid levels. Clinical studies have shown that in the treatment of hyperuricemia in patients with gout, it can not only help patients achieve the target serum uric acid level rapidly, but also has higher medication safety for patients with renal insufficiency, filling the application gap of traditional uricosuric drugs in people with renal impairment.

At present, remepiazine is in the early stage of global commercialization, and there is no verifiable public market size and growth data for the time being. As a new generation of uric acid-lowering drugs, its potential market space is mainly driven by the growth of the gout patient base and the tolerance defects of existing treatment regimens. If it is successfully approved for marketing in major markets in the future, it is expected to reshape the competitive landscape of uricosuric drugs.

The original research enterprise of remepiazine is Jiangsu Hengrui Pharmaceutical Co., Ltd., and the original brand name is Ruitantong®. Its core compound patent in China will expire in 2042. The currently approved main dosage form is tablet, with a specification of 20mg. This product was approved for marketing by the China NMPA in 2024, and has been included in the China Listed Medicines Catalogue as a reference preparation; its active pharmaceutical ingredient (API) has completed registration with the CDE. The relevant preparation is the first remepiazine preparation approved for marketing in China, and there is no overseas approval record for the time being. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of impurity reference standards for remepiazine, most of which are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. The products fully comply with the regulatory requirements of the Chinese Pharmacopoeia and FDA, and can provide reliable reference standard support for the whole process of pharmaceutical enterprises' work, including API quality research, preparation stability investigation, and application document preparation, helping enterprises shorten the R&D cycle and reduce compliance risks.